Hookipa is starting its first clinical trial for a vaccine against human cytomegalovirus. This is the leading candidate of its platform for novel viral vectors, which promises to yield better vaccines for infections and cancer.
Based in Vienna, Hookipa was founded in 2011 and is developing a new class of immunotherapies. Its strategy for novel viral vectors already attracted €27M from top Biotech investors in Europe like Sofinnova and Forbion.
Just last month, the Biotech also appointed new CEO – Joern Aldag, a Biotech veteran who we recently interviewed about his really successful career. Hookipa is keeping its momentum, now beginning its first clinical trial.
The trial is a Phase I study to assess the safety of the Biotech’s leading candidate, the HB-101 vaccine for the prevention of human cytomegalovirus (hCMV). This virus is one of the most significant infections for immunocompromised patients and during pregnancy. As hCMV is still without a vaccine, it has been ranked at the highest priority by health authorities.